-
Je něco špatně v tomto záznamu ?
Wash-resistantly bound xanomeline inhibits acetylcholine release by persistent activation of presynaptic M(2) and M(4) muscarinic receptors in rat brain
Machová E, Jakubík J, El-Fakahany EE, Dolezal V.
Jazyk angličtina Země Spojené státy americké
NLK
Open Access Digital Library
od 1997-01-01 do Před 1 rokem
ASPET Journals
od 1997 do 2013
- MeSH
- acetylcholin sekrece MeSH
- agonisté muskarinových receptorů metabolismus MeSH
- CHO buňky MeSH
- financování organizované MeSH
- křečci praví MeSH
- krysa rodu rattus MeSH
- lidé MeSH
- mozková kůra sekrece účinky léků MeSH
- noradrenalin sekrece MeSH
- potkani Wistar MeSH
- pyridiny farmakologie MeSH
- receptor muskarinový M2 fyziologie účinky léků MeSH
- receptor muskarinový M4 fyziologie účinky léků MeSH
- thiadiazoly farmakologie MeSH
- zvířata MeSH
- Check Tag
- křečci praví MeSH
- krysa rodu rattus MeSH
- lidé MeSH
- mužské pohlaví MeSH
- zvířata MeSH
We studied the effects of 3-[3-hexyloxy-1,2,5-thiadiazo-4-yl]-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) wash-resistant binding on presynaptic muscarinic regulation of electrically evoked [(3)H]acetylcholine (ACh) release from rat brain slices. In both cortical and striatal tissues that possess M(2) and M(4) autoreceptors, respectively, immediate application of 10 microM xanomeline had no effect on evoked [(3)H]ACh release or its inhibition by 10 microM carbachol. In contrast, preincubation with 1, 10, or 100 microM xanomeline for 15 min decreased evoked release of ACh measured after 53 min of washing in xanomeline-free medium in a concentration-dependent manner. The maximal inhibitory effect equaled the immediate effect of the muscarinic full agonist carbachol, and it was completely (at 1 and 10 microM xanomeline) or partially (at 100 microM xanomeline) blocked by 1 microM N-methylscopolamine. Neither presence of N-methylscopolamine during 100 microM xanomeline treatment nor previous irreversible inactivation of the classical receptor binding site using propylbenzylcholine mustard in cortical slices prevented the inhibitory effect of wash-resistantly bound xanomeline. Treatment of cortical slices with xanomeline slightly decreased the number of muscarinic binding sites, and it markedly decreased affinity for N-methylscopolamine. When applied as in acetylcholine release experiments, xanomeline did not impair presynaptic alpha(2)-adrenoceptor-mediated regulation of noradrenaline release. The functional studies in brain tissue reported in this work demonstrate that xanomeline can function as a wash-resistant agonist of native presynaptic muscarinic M(2) and M(4) receptors with both competitive and allosteric components of action.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10000627
- 003
- CZ-PrNML
- 005
- 20200313100719.0
- 008
- 100112s2007 xxu e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Machová, Eva. $7 _AN045395
- 245 10
- $a Wash-resistantly bound xanomeline inhibits acetylcholine release by persistent activation of presynaptic M(2) and M(4) muscarinic receptors in rat brain / $c Machová E, Jakubík J, El-Fakahany EE, Dolezal V.
- 314 __
- $a Institute of Physiology, Czech Academy of Sciences, Vídenská 1083, 14220 Prague, Czech Republic
- 520 9_
- $a We studied the effects of 3-[3-hexyloxy-1,2,5-thiadiazo-4-yl]-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) wash-resistant binding on presynaptic muscarinic regulation of electrically evoked [(3)H]acetylcholine (ACh) release from rat brain slices. In both cortical and striatal tissues that possess M(2) and M(4) autoreceptors, respectively, immediate application of 10 microM xanomeline had no effect on evoked [(3)H]ACh release or its inhibition by 10 microM carbachol. In contrast, preincubation with 1, 10, or 100 microM xanomeline for 15 min decreased evoked release of ACh measured after 53 min of washing in xanomeline-free medium in a concentration-dependent manner. The maximal inhibitory effect equaled the immediate effect of the muscarinic full agonist carbachol, and it was completely (at 1 and 10 microM xanomeline) or partially (at 100 microM xanomeline) blocked by 1 microM N-methylscopolamine. Neither presence of N-methylscopolamine during 100 microM xanomeline treatment nor previous irreversible inactivation of the classical receptor binding site using propylbenzylcholine mustard in cortical slices prevented the inhibitory effect of wash-resistantly bound xanomeline. Treatment of cortical slices with xanomeline slightly decreased the number of muscarinic binding sites, and it markedly decreased affinity for N-methylscopolamine. When applied as in acetylcholine release experiments, xanomeline did not impair presynaptic alpha(2)-adrenoceptor-mediated regulation of noradrenaline release. The functional studies in brain tissue reported in this work demonstrate that xanomeline can function as a wash-resistant agonist of native presynaptic muscarinic M(2) and M(4) receptors with both competitive and allosteric components of action.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a acetylcholin $x sekrece $7 D000109
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a CHO buňky $7 D016466
- 650 _2
- $a mozková kůra $x sekrece $x účinky léků $7 D002540
- 650 _2
- $a křečci praví $7 D006224
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a agonisté muskarinových receptorů $x metabolismus $7 D018721
- 650 _2
- $a noradrenalin $x sekrece $7 D009638
- 650 _2
- $a pyridiny $x farmakologie $7 D011725
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a receptor muskarinový M2 $x fyziologie $x účinky léků $7 D043585
- 650 _2
- $a receptor muskarinový M4 $x fyziologie $x účinky léků $7 D043588
- 650 _2
- $a thiadiazoly $x farmakologie $7 D013830
- 700 1_
- $a Jakubík, Jan. $7 xx0281420
- 700 1_
- $a El-Fakahany, Esam E. $7 xx0067696
- 700 1_
- $a Doležal, Vladimír, $d 1952 červen 12.- $7 nlk19990073099
- 773 0_
- $w MED00002900 $t The journal of pharmacology and experimental therapeutics $g Roč. 322, č. 1 (2007), s. 316-323 $x 0022-3565
- 910 __
- $a ABA008 $b x $y 8 $z 0
- 990 __
- $a 20090310084605 $b ABA008
- 991 __
- $a 20200313101139 $b ABA008
- 999 __
- $a ok $b bmc $g 703356 $s 565795
- BAS __
- $a 3
- BMC __
- $a 2007 $b 322 $c 1 $d 316-323 $i 0022-3565 $m The Journal of pharmacology and experimental therapeutics $x MED00002900
- LZP __
- $a 2010-b1/ipme